Phaseline

Targets › CYP21A2

CYP21A2 (Steroid 21-hydroxylase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Feb 2029.

A cytochrome P450 monooxygenase that plays a major role in adrenal steroidogenesis. Catalyzes the hydroxylation at C-21 of progesterone and 17alpha-hydroxyprogesterone to respectively form 11-deoxycorticosterone and 11-deoxycortisol, intermediate metabolites in the biosynthetic pathway of mineralocorticoids and glucocorticoids. (UniProt, P08686)

Open in Phaseline: the race on CYP21A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Adrenas TherapeuticsAAV BBP-631
AAV5-mediated gene therapy delivering CYP21A2
CYP21A2Phase 1Congenital Adrenal HyperplasiaFeb 2029

Conditions

Congenital Adrenal Hyperplasia (1)

Modalities

other (1)

Companies

Adrenas Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.